Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Recurrent or Metastatic Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,048 result(s) found for: Recurrent or Metastatic Cancer AND Cancer. Displaying page 24 of 53.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    EudraCT Number: 2017-002824-26 Sponsor Protocol Number: VHIO17001 Start Date*: 2018-02-23
    Sponsor Name:Vall d' Hebron Institute of Oncology (VHIO)
    Full Title: Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)
    Medical condition: Advanced, Recurrent or Metastatic Endometrial Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007129 Cancer-related morbidities HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001537-24 Sponsor Protocol Number: EMR100070-005 Start Date*: 2015-12-14
    Sponsor Name:Merck KGaA
    Full Title: A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer
    Medical condition: First Line Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) PT (Completed) LT (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) HU (Completed) PL (Completed) NL (Completed) FR (Completed) DK (Completed) BG (Completed) HR (Completed) CY (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003757-28 Sponsor Protocol Number: CRAD001Y2201 Start Date*: 2013-02-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen r...
    Medical condition: Estrogen receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed) GB (Completed) IE (Completed) DK (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-003844-31 Sponsor Protocol Number: H6Q-MC-S064 Start Date*: 2007-11-28
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
    Medical condition: Locally advanced or metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005477-31 Sponsor Protocol Number: I4C-MC-JTBC Start Date*: 2013-08-27
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005910-17 Sponsor Protocol Number: KKSH176 Start Date*: 2021-06-01
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned fo...
    Medical condition: Recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002472-34 Sponsor Protocol Number: EGF109462 Start Date*: 2007-08-06
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
    Medical condition: Patients with advanced or metatstatic Non-Small Cell Lung Cancer who have received one prior platinum containing chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003751-19 Sponsor Protocol Number: PCIA202/10 Start Date*: 2012-01-27
    Sponsor Name:PCI Biotech AS
    Full Title: An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and n...
    Medical condition: Recurrent head and neck squamous cell carcinoma (HNSCC) insuitable for surgery and radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000325-21 Sponsor Protocol Number: A6181122 Start Date*: 2007-05-02
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT
    Medical condition: first-line treatment of patients with metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IE (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000309-21 Sponsor Protocol Number: UCa-001 Start Date*: 2018-10-31
    Sponsor Name:Inovio Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
    Medical condition: Locally advanced unresectable or metastatic/recurrent Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077056 Urothelial carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003636-36 Sponsor Protocol Number: UCL/17/0396 Start Date*: 2019-01-08
    Sponsor Name:University College London
    Full Title: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
    Medical condition: Recurrent/metastatic head and neck squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-006459-10 Sponsor Protocol Number: KU36-58 Start Date*: 2007-07-18
    Sponsor Name:KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies)
    Full Title: A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associat...
    Medical condition: Advanced ovarian cancer (stage IIIB/IIIC/IV) and confirmed BRCA+ status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002124-21 Sponsor Protocol Number: GINECO-EN105b Start Date*: 2021-12-21
    Sponsor Name:ARCAGY-GINECO
    Full Title: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGO...
    Medical condition: Endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004803-36 Sponsor Protocol Number: 1199.13 Start Date*: 2009-03-30
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy i...
    Medical condition: stage IIIB/IV or recurrent non small cell lung cancer after failure of first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) DK (Completed) LT (Completed) ES (Completed) SK (Completed) GB (Completed) FR (Completed) PT (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014440-10 Sponsor Protocol Number: EMR200068-006 Start Date*: 2009-12-03
    Sponsor Name:Merck KGaA
    Full Title: A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squ...
    Medical condition: Recurrent/metastatic squamous cell cancer of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) FR (Completed) SK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001892-35 Sponsor Protocol Number: MK-7339-009 Start Date*: 2019-12-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab ...
    Medical condition: Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022240-21 Sponsor Protocol Number: ISIS183750-CS4 Start Date*: 2011-04-29
    Sponsor Name:Isis Pharmaceuticals Inc.
    Full Title: A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer
    Medical condition: Stage IV Non-Small Cell Lung Cancer (NSCLC; including patients with pleural effusion who were previously classified as Stage IIIB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002164-13 Sponsor Protocol Number: UZBRU_VHH1_3 Start Date*: 2017-01-05
    Sponsor Name:UZ Brussel
    Full Title: Quantification of 68GaNOTA-Anti-HER2 VHH1 Uptake in metastasis of Breast carcinoma and cancer patients and Assessment of Repeatability – Pilot study
    Medical condition: Breast cancer; salivary gland cancer; adenocarcinoma of the gastric body or gastro-esophageal junction; endometrial cancer; cancer of cervix uteri; Non-small cell lung cancer; biliary tract cancer;...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004627-33 Sponsor Protocol Number: GSN000400 Start Date*: 2022-02-03
    Sponsor Name:Genkyotex Suisse SA
    Full Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxi...
    Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002030-36 Sponsor Protocol Number: CA2097DX Start Date*: 2019-11-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer
    Medical condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) FR (Completed) BE (Completed) CZ (Completed) IT (Completed) RO (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 08:26:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA